Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
$154.88
-0.7%
$166.19
$56.10
$200.00
$6.23B-1.19119,807 shs59,970 shs
CG Oncology, Inc. stock logo
CGON
CG Oncology
$69.62
+0.6%
$65.66
$23.32
$73.56
$6.09B0.41947,951 shs1.14 million shs
Damora Therapeutics, Inc. Common Stock stock logo
DMRA
Damora Therapeutics, Inc. Common Stock
$24.16
-3.3%
$26.29
$2.45
$38.33
$1.51B1.5311,492 shs171,305 shs
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
$52.95
$49.68
$2.65
$53.19
$6.12B-0.374.84 million shs6.35 million shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
0.00%-1.99%-12.72%-16.96%+157.23%
CG Oncology, Inc. stock logo
CGON
CG Oncology
0.00%+3.66%+0.45%+37.37%+209.67%
Damora Therapeutics, Inc. Common Stock stock logo
DMRA
Damora Therapeutics, Inc. Common Stock
0.00%-2.61%-2.38%-1.07%+825.56%
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
0.00%+0.04%+0.55%+40.34%+1,650.41%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
$154.88
-0.7%
$166.19
$56.10
$200.00
$6.23B-1.19119,807 shs59,970 shs
CG Oncology, Inc. stock logo
CGON
CG Oncology
$69.62
+0.6%
$65.66
$23.32
$73.56
$6.09B0.41947,951 shs1.14 million shs
Damora Therapeutics, Inc. Common Stock stock logo
DMRA
Damora Therapeutics, Inc. Common Stock
$24.16
-3.3%
$26.29
$2.45
$38.33
$1.51B1.5311,492 shs171,305 shs
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
$52.95
$49.68
$2.65
$53.19
$6.12B-0.374.84 million shs6.35 million shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
0.00%-1.99%-12.72%-16.96%+157.23%
CG Oncology, Inc. stock logo
CGON
CG Oncology
0.00%+3.66%+0.45%+37.37%+209.67%
Damora Therapeutics, Inc. Common Stock stock logo
DMRA
Damora Therapeutics, Inc. Common Stock
0.00%-2.61%-2.38%-1.07%+825.56%
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
0.00%+0.04%+0.55%+40.34%+1,650.41%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
2.63
Moderate Buy$202.3330.64% Upside
CG Oncology, Inc. stock logo
CGON
CG Oncology
2.77
Moderate Buy$79.5514.26% Upside
Damora Therapeutics, Inc. Common Stock stock logo
DMRA
Damora Therapeutics, Inc. Common Stock
2.88
Moderate Buy$43.4079.64% Upside
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
2.27
Hold$55.144.13% Upside

Current Analyst Ratings Breakdown

Latest DMRA, BLTE, TERN, and CGON Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/27/2026
CG Oncology, Inc. stock logo
CGON
CG Oncology
Boost Price TargetOutperform$73.00 ➝ $79.00
4/27/2026
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
Reiterated RatingOutperformMarket Perform$58.00
4/26/2026
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
DowngradeOutperformMarket Perform
4/24/2026
Damora Therapeutics, Inc. Common Stock stock logo
DMRA
Damora Therapeutics, Inc. Common Stock
Initiated CoverageOutperform$40.00
4/23/2026
Damora Therapeutics, Inc. Common Stock stock logo
DMRA
Damora Therapeutics, Inc. Common Stock
UpgradeModerate Buy
4/22/2026
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
Reiterated RatingBuy$200.00
4/20/2026
CG Oncology, Inc. stock logo
CGON
CG Oncology
Reiterated RatingSell (D-)
4/17/2026
CG Oncology, Inc. stock logo
CGON
CG Oncology
Boost Price TargetOverweight$65.00 ➝ $91.00
4/14/2026
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
Boost Price TargetOverweight$44.00 ➝ $44.50
4/13/2026
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
Reiterated RatingBuy$200.00
4/8/2026
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
DowngradeStrong-BuyHold
(Data available from 5/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
N/AN/AN/AN/A$20.54 per shareN/A
CG Oncology, Inc. stock logo
CGON
CG Oncology
$4.04M1,516.65N/AN/A$9.33 per share7.46
Damora Therapeutics, Inc. Common Stock stock logo
DMRA
Damora Therapeutics, Inc. Common Stock
N/AN/AN/AN/A($110.11) per shareN/A
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
N/AN/AN/AN/A$9.70 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
-$77.61M-$2.30N/AN/AN/AN/A-19.49%-19.05%5/12/2026 (Estimated)
CG Oncology, Inc. stock logo
CGON
CG Oncology
-$160.99M-$2.07N/AN/AN/AN/A-22.87%-21.82%N/A
Damora Therapeutics, Inc. Common Stock stock logo
DMRA
Damora Therapeutics, Inc. Common Stock
-$209.84M-$12.10N/AN/AN/AN/A-147.05%-279.49%N/A
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
-$96.21M-$1.03N/AN/AN/AN/A-20.02%-19.37%5/14/2026 (Estimated)

Latest DMRA, BLTE, TERN, and CGON Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2026Q1 2026
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
-$0.30N/AN/AN/AN/AN/A
5/12/2026Q1 2026
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
-$0.60N/AN/AN/AN/AN/A
5/8/2026Q1 2026
CG Oncology, Inc. stock logo
CGON
CG Oncology
-$0.59-$0.71-$0.12-$0.71$0.45 million$1.08 million
3/30/2026Q4 2025
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
-$0.30-$0.24+$0.06-$0.24N/AN/A
3/2/2026Q4 2025
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
-$0.56-$0.38+$0.18-$0.70N/AN/A
2/27/2026Q4 2025
CG Oncology, Inc. stock logo
CGON
CG Oncology
-$0.61-$0.51+$0.10-$0.51N/A$2.32 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
N/AN/AN/AN/AN/A
CG Oncology, Inc. stock logo
CGON
CG Oncology
N/AN/AN/AN/AN/A
Damora Therapeutics, Inc. Common Stock stock logo
DMRA
Damora Therapeutics, Inc. Common Stock
N/AN/AN/AN/AN/A
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
N/A
50.02
50.02
CG Oncology, Inc. stock logo
CGON
CG Oncology
N/A
24.63
24.58
Damora Therapeutics, Inc. Common Stock stock logo
DMRA
Damora Therapeutics, Inc. Common Stock
N/A
12.98
12.98
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
N/A
62.41
62.41

Institutional Ownership

CompanyInstitutional Ownership
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
0.53%
CG Oncology, Inc. stock logo
CGON
CG Oncology
26.56%
Damora Therapeutics, Inc. Common Stock stock logo
DMRA
Damora Therapeutics, Inc. Common Stock
14.20%
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
98.26%
CompanyEmployeesShares OutstandingFree FloatOptionable
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
1039.97 million34.65 millionNot Optionable
CG Oncology, Inc. stock logo
CGON
CG Oncology
6188.01 million83.79 millionOptionable
Damora Therapeutics, Inc. Common Stock stock logo
DMRA
Damora Therapeutics, Inc. Common Stock
4060.30 million54.00 millionNo Data
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
40115.52 million113.79 millionNot Optionable

Recent News About These Companies

Merck completes acquisition of Terns Pharmaceuticals
Merck's Keytruda Surge: A Boost Amid Acquisition Costs

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Belite Bio stock logo

Belite Bio NASDAQ:BLTE

$154.88 -1.12 (-0.72%)
Closing price 05/8/2026 04:00 PM Eastern
Extended Trading
$155.24 +0.36 (+0.23%)
As of 05/8/2026 07:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients. It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy that is in the preclinical development phase targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.

CG Oncology stock logo

CG Oncology NASDAQ:CGON

$69.62 +0.44 (+0.64%)
Closing price 05/8/2026 04:00 PM Eastern
Extended Trading
$69.62 0.00 (0.00%)
As of 05/8/2026 06:26 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.

Damora Therapeutics, Inc. Common Stock stock logo

Damora Therapeutics, Inc. Common Stock NASDAQ:DMRA

$24.16 -0.83 (-3.32%)
As of 05/8/2026 04:00 PM Eastern

Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.

Terns Pharmaceuticals stock logo

Terns Pharmaceuticals NASDAQ:TERN

$52.95 0.00 (0.00%)
As of 05/5/2026 03:30 PM Eastern

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of MASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.